Ribbon Acquisition Corp. (RIBB) to Combine with DRC Medicine in $422M Deal
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million
Read More
To access this post, you must purchase 1 - User: Monthly Plan.